Latest Conference Articles

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

Robert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.

The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

HPV vaccination may offer protection against HPV-related cancers across multiple tumor sites in women aged 18-25 who had been previously exposed to HPV.

Frontline immunotherapy with nivolumab plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma.

F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive non–small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.

Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBV–associated lymphoproliferative disorders.

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.

Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib in the treatment of women with ovarian cancer, according to Ursula A. Matulonis, MD.

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

The prospects for combining anti–PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).